BIO-Europe Spring® 2016: PledPharma seeks partner for lead therapy

April 28, 2016
Jacques Näsström, CEO of Pled Pharma, chats with Sten Stovall, senior editor at Pharma Intelligence, about the company’s current hunt for licensing partners for lead product PledOx (calmangafodipir), which is being developed as a preventative therapy against nerve damage associated with cytotoxic therapy in colorectal cancer patients. They also discuss a regulatory pathway for PledOx and development plans for the company's other pipeline assets.
Previous Video
BIO-Europe Spring® 2016: How to get Takeda Ventures to notice your startup
BIO-Europe Spring® 2016: How to get Takeda Ventures to notice your startup

Dr. Ilan Zipkin, senior investment director at Takeda Ventures, talks with Mike Ward, global director of co...

Next Video
BIO-Europe Spring® 2016: ReViral sets out clinical data timeline for RSV therapy
BIO-Europe Spring® 2016: ReViral sets out clinical data timeline for RSV therapy

Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, chats with chie...